Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

A high burden of heart valve diseases is driving its expansion. India’s transcatheter aortic valve replacement (TAVR) market ...

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

HYDERABAD: Doctors at Citizens Hospital successfully treated a 72-year-old patient with severe aortic valve stenosis and ...

Despite guideline recommendations, the use of bioprosthetic heart valves has surpassed mechanical valves, but data from a large surgical database may lead to a reassessment of that practice.

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.